Apyx Medical Corp: Form 10-K for the period ended Dec 31, 2017
Filed with the SEC on Mar 13, 2018 and accepted by EDGAR at Mar 13, 2018, 07:31 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2017-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2017-10-01 to 2017-12-31 | $11.3m | us-gaap:SalesRevenueNet |
| Cost of revenue | 12 months2017-01-01 to 2017-12-31 | $19.1m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months2017-10-01 to 2017-12-31 | $5.9m | us-gaap:GrossProfit |
| Gross profit | 12 months2017-01-01 to 2017-12-31 | $19.8m | us-gaap:GrossProfit |
| Research and development | 12 months2017-01-01 to 2017-12-31 | $2.5m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 12 months2017-01-01 to 2017-12-31 | $11.4m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 12 months2017-01-01 to 2017-12-31 | −$5.3m | us-gaap:OperatingIncomeLoss |
| Income tax | 12 months2017-01-01 to 2017-12-31 | −$156.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2017-10-01 to 2017-12-31 | −$824.0k | us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic |
| Net income | 12 months2017-01-01 to 2017-12-31 | −$5.1m | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months2017-01-01 to 2017-12-31 | −$0.17 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2017-10-01 to 2017-12-31 | −$0.03 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 12 months2017-01-01 to 2017-12-31 | −$0.16 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months2017-01-01 to 2017-12-31 | 31,427,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months2017-01-01 to 2017-12-31 | −$3.7m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2017-01-01 to 2017-12-31 | $624.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2017-12-31 | $9.9m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2017-12-31 | $22.5m | us-gaap:AssetsCurrent |
| Total assets | At period end2017-12-31 | $31.0m | us-gaap:Assets |
| Current liabilities | At period end2017-12-31 | $6.0m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2017-12-31 | $9.0m | us-gaap:Liabilities |
| Long-term debt | At period end2017-12-31 | $2.5m | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2017-12-31 | $239.0k | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | At period end2017-12-31 | $22.0m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0000719135-18-000015. Last ingested by Listed: Nov 5, 2026, 13:09 ET. Listed shows no prices and gives no investment advice.